Sumona Chaudhury1, Paige L Williams1,2, Gloria K Mayondi3, Jean Leidner4, Penny Holding5, Vicki Tepper6, Sharon Nichols7, Jane Magetse3, Maureen Sakoi3, Kebaiphe Moabi3, Joseph Makhema3, Charlotte Mdluli3, Haruna Jibril8, George R Seage1, Betsy Kammerer9,10, Shahin Lockman11,10,12,13. 1. Departments of Epidemiology. 2. Biostatistics. 3. Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana. 4. Goodtables Data Consulting, Norman, Oklahoma. 5. Educate Africa, Mombasa, Kenya. 6. Department of Pediatrics, School of Medicine, University of Maryland, Baltimore, Maryland. 7. Department of Neurosciences, University of California, San Diego, California. 8. Ministry of Health Botswana, Gaborone, Botswana. 9. Department of Psychiatry, Boston Children's Hospital, Boston, Massachusetts; and. 10. Brigham and Women's Hospital, Boston, Massachusetts. 11. Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana; sumona@mail.harvard.edu. 12. Immunology, and. 13. Infectious Diseases, Harvard T.H. Chan School of Public Health, Harvard University, Boston, Massachusetts.
Abstract
BACKGROUND: We sought to determine if HIV-exposed uninfected (HEU) children had worse neurodevelopmental outcomes at 24 months compared with HIV-unexposed uninfected (HUU) children in Botswana. METHODS: HIV-infected and uninfected mothers enrolled in a prospective observational study ("Tshipidi") in Botswana from May 2010 to July 2012. Child neurodevelopment was assessed at 24 months with the Bayley Scales of Infant and Toddler Development, Third Edition (Bayley-III: cognitive, gross motor, fine motor, expressive language, and receptive language domains) and the Development Milestones Checklist (DMC), a caregiver-completed questionnaire (locomotor, fine motor, language and personal-social domains). We used linear regression models to estimate the association of in-utero HIV exposure with neurodevelopment, adjusting for socioeconomic and maternal health characteristics. RESULTS: We evaluated 670 children (313 HEU, 357 HUU) with ≥1 valid Bayley-III domain assessed and 723 children (337 HEU, 386 HUU) with a DMC. Among the 337 HEU children with either assessment, 122 (36%) were exposed in utero to maternal 3-drug antiretroviral treatment and 214 (64%) to zidovudine. Almost all HUU children (99.5%) breastfed, compared with only 9% of HEU children. No domain score was significantly lower among HEU children in adjusted analyses. Bayley-III cognitive and DMC personal-social domain scores were significantly higher in HEU children than in HUU children, but differences were small. CONCLUSIONS: HEU children performed equally well on neurodevelopmental assessments at 24 months of age compared with HUU children. Given the global expansion of the HEU population, results suggesting no adverse impact of in-utero HIV and antiretroviral exposure on early neurodevelopment are reassuring.
BACKGROUND: We sought to determine if HIV-exposed uninfected (HEU) children had worse neurodevelopmental outcomes at 24 months compared with HIV-unexposed uninfected (HUU) children in Botswana. METHODS:HIV-infected and uninfected mothers enrolled in a prospective observational study ("Tshipidi") in Botswana from May 2010 to July 2012. Child neurodevelopment was assessed at 24 months with the Bayley Scales of Infant and Toddler Development, Third Edition (Bayley-III: cognitive, gross motor, fine motor, expressive language, and receptive language domains) and the Development Milestones Checklist (DMC), a caregiver-completed questionnaire (locomotor, fine motor, language and personal-social domains). We used linear regression models to estimate the association of in-utero HIV exposure with neurodevelopment, adjusting for socioeconomic and maternal health characteristics. RESULTS: We evaluated 670 children (313 HEU, 357 HUU) with ≥1 valid Bayley-III domain assessed and 723 children (337 HEU, 386 HUU) with a DMC. Among the 337 HEU children with either assessment, 122 (36%) were exposed in utero to maternal 3-drug antiretroviral treatment and 214 (64%) to zidovudine. Almost all HUU children (99.5%) breastfed, compared with only 9% of HEU children. No domain score was significantly lower among HEU children in adjusted analyses. Bayley-III cognitive and DMC personal-social domain scores were significantly higher in HEU children than in HUU children, but differences were small. CONCLUSIONS: HEU children performed equally well on neurodevelopmental assessments at 24 months of age compared with HUU children. Given the global expansion of the HEU population, results suggesting no adverse impact of in-utero HIV and antiretroviral exposure on early neurodevelopment are reassuring.
Authors: D Drotar; K Olness; M Wiznitzer; L Guay; L Marum; G Svilar; D Hom; J F Fagan; C Ndugwa; R Kiziri-Mayengo Journal: Pediatrics Date: 1997-07 Impact factor: 7.124
Authors: Elizabeth L Prado; Amina A Abubakar; Souheila Abbeddou; Elizabeth Y Jimenez; Jérôme W Somé; Jean-Bosco Ouédraogo Journal: Acta Paediatr Date: 2014-01-07 Impact factor: 2.299
Authors: Ellen C Caniglia; Kunjal Patel; Yanling Huo; Paige L Williams; Suad Kapetanovic; Kenneth C Rich; Patricia A Sirois; Denise L Jacobson; Sonia Hernandez-Diaz; Miguel A Hernán; George R Seage Journal: AIDS Date: 2016-05-15 Impact factor: 4.177
Authors: Paige L Williams; Miguel Marino; Kathleen Malee; Susan Brogly; Michael D Hughes; Lynne M Mofenson Journal: Pediatrics Date: 2010-01-18 Impact factor: 7.124
Authors: Hannah Blencowe; Anne C C Lee; Simon Cousens; Adil Bahalim; Rajesh Narwal; Nanbert Zhong; Doris Chou; Lale Say; Neena Modi; Joanne Katz; Theo Vos; Neil Marlow; Joy E Lawn Journal: Pediatr Res Date: 2013-12 Impact factor: 3.756
Authors: Stanzi M le Roux; Kirsten A Donald; Kirsty Brittain; Tamsin K Phillips; Allison Zerbe; Kelly K Nguyen; Andrea Strandvik; Max Kroon; Elaine J Abrams; Landon Myer Journal: AIDS Date: 2018-08-24 Impact factor: 4.177
Authors: Michael J Boivin; Limbika Maliwichi-Senganimalunje; Lillian W Ogwang; Rachel Kawalazira; Alla Sikorskii; Itziar Familiar-Lopez; Agatha Kuteesa; Mary Nyakato; Alex Mutebe; Jackie L Namukooli; MacPherson Mallewa; Horacio Ruiseñor-Escudero; Jim Aizire; Taha E Taha; Mary G Fowler Journal: Lancet HIV Date: 2019-05-20 Impact factor: 12.767
Authors: Rachel S Gruver; Sumaya Mall; Jane D Kvalsvig; Justin R Knox; Claude A Mellins; Chris Desmond; Shuaib Kauchali; Stephen M Arpadi; Myra Taylor; Leslie L Davidson Journal: New Dir Child Adolesc Dev Date: 2020-07-03
Authors: Thomas Struyf; Queen Dube; Elizabeth A Cromwell; Anna D Sheahan; Robert S Heyderman; Annelies Van Rie Journal: Eur J Paediatr Neurol Date: 2019-11-21 Impact factor: 3.140
Authors: Gbolahan Ajibola; Jean Leidner; Gloria K Mayondi; Erik van Widenfelt; Tebogo Madidimalo; Chipo Petlo; Sikhulile Moyo; Mompati Mmalane; Paige L Williams; Adam R Cassidy; Roger Shapiro; Betsy Kammerer; Shahin Lockman Journal: J Pediatr Date: 2018-10-11 Impact factor: 4.406